首页GLSHQ • OTCMKTS
add
Gelesis Holdings Inc
市场资讯
财务信息
损益表
收入
净收入
| (USD) | 2023年6月info | 年同比变化 |
|---|---|---|
收入 | 110.70万 | — |
经营支出 | 1060.50万 | — |
净收入 | -768.10万 | — |
净利润率 | -693.86 | — |
每股收益 | — | — |
息税折旧摊销前利润 | -793.00万 | — |
有效税率 | — | — |
资产负债表
总资产
负债总额
| (USD) | 2023年6月info | 年同比变化 |
|---|---|---|
现金及短期投资 | 790.90万 | — |
总资产 | 9587.50万 | — |
负债总额 | 1.14亿 | — |
权益总额 | -1862.50万 | — |
发行在外的股份 | 7333.51万 | — |
市净率 | -0.00 | — |
资产回报率 | -25.68% | — |
资本回报率 | -55.33% | — |
现金流
现金净变动
| (USD) | 2023年6月info | 年同比变化 |
|---|---|---|
净收入 | -768.10万 | — |
来自运营的现金 | 61.70万 | — |
投资现金 | -1.80万 | — |
融资现金 | 417.30万 | — |
现金净变动 | 480.60万 | — |
自由现金流 | 382.14万 | — |
简介
Gelesis is a biotechnology company located in Boston, Massachusetts that developed the weight loss device Gelesis100 for use in overweight and obesity. The company produces Gelesis100, which is a superabsorbent hydrogel capsule that expands in the stomach, creating a feeling of fullness, helping people reduce the amount of food they eat. The company was founded in 2006 to develop medical devices and treatments for obesity.
Gelesis Holdings, Inc. together with its two affiliates, filed for voluntary Chapter 7 liquidation in the United States Bankruptcy Court for the District of Delaware on October 30, 2023. The debtor listed its assets among the 50 and the $100 million and liabilities of $44.34 million. The Debtor is represented by Kenneth Listwak of Troutman Pepper Hamilton Sanders LLP as counsel. Wikipedia
成立时间
2006
员工数量
93
